2021
Facility-Level Variation in Use of Locoregional Therapy for Metastatic Prostate Cancer
Buck M, Ghiraldi E, Demkowicz P, Park H, An Y, Kann B, Yu J, Sprenkle P, Kim I, Leapman M. Facility-Level Variation in Use of Locoregional Therapy for Metastatic Prostate Cancer. Urology Practice 2021, 9: 141-149. PMID: 37145694, DOI: 10.1097/upj.0000000000000290.Peer-Reviewed Original ResearchMetastatic prostate cancerLocal therapyProstate cancerLocoregional therapyFacility-level useFacility-level variationM1 prostate cancerDefinitive local therapyNational Cancer DatabaseMetastatic prostate adenocarcinomaClinical practice guidelinesMultilevel logistic regressionM1 diseasePatient factorsTherapy useUninsured statusRadical prostatectomyCancer DatabaseProstate adenocarcinomaHigh comorbidityLocal treatmentPatient levelPractice guidelinesLower oddsPatients
2017
Trends and Clinico-Sociodemographic Determinants of Stereotactic Body Radiation Therapy Use for Localized Prostate Cancer
Mahal B, Sethi R, Chen Y, Casey D, Yang D, Muralidhar V, Mahal A, Orio P, Nguyen P, Yu J. Trends and Clinico-Sociodemographic Determinants of Stereotactic Body Radiation Therapy Use for Localized Prostate Cancer. International Journal Of Radiation Oncology • Biology • Physics 2017, 99: e254. DOI: 10.1016/j.ijrobp.2017.06.1209.Peer-Reviewed Original Research
2016
National trends and determinants of proton therapy use for prostate cancer: A National Cancer Data Base study
Mahal B, Chen Y, Efstathiou J, Muralidhar V, Hoffman K, Yu J, Feng F, Beard C, Martin N, Orio P, Nguyen P. National trends and determinants of proton therapy use for prostate cancer: A National Cancer Data Base study. Cancer 2016, 122: 1505-1512. PMID: 26970022, DOI: 10.1002/cncr.29960.Peer-Reviewed Original ResearchConceptsProton therapy useProstate cancerProton therapyTherapy useIncreasing use of proton therapyMultivariable adjustmentUse of proton therapyNational Cancer Data BaseLong-term follow-upExternal beam radiotherapyMultivariate logistic regression analysisHigh-grade diseaseNonmetastatic prostate cancerFactors associated with receiptNationwide cancer registryLogistic regression analysisBeam radiotherapyDefinitive therapyOncological therapyNonacademic centersTreated patientsClinical factorsFollow-upProstateCancer Registry
2015
Trends in Adjuvant and Neoadjuvant Radiotherapy for Cancer Treatment From 1973 to 2011
Le Bui D, Yu J. Trends in Adjuvant and Neoadjuvant Radiotherapy for Cancer Treatment From 1973 to 2011. The Cancer Journal 2015, 21: 147-149. PMID: 26049692, DOI: 10.1097/ppo.0000000000000114.Peer-Reviewed Original ResearchConceptsNeoadjuvant radiation therapyRadiation therapyThyroid cancerCervical cancerKidney cancerRadiation therapy useEnd Results databaseCancer-directed surgeryPercentage of patientsCoordinated careNeoadjuvant radiotherapyOral cavity/pharynxOvarian cancerProstate cancerResults databaseUterine cancerGenitourinary cancersOral cavityPancreatic cancerBladder cancerTherapy useMultidisciplinary clinical teamBreast cancerDisease sitesTherapy usage
2012
The relations between age and androgen deprivation therapy use among men receiving radiation therapy for prostate cancer in the Medicare population.
Quon J, Yu J, Soulos P, Gross C. The relations between age and androgen deprivation therapy use among men receiving radiation therapy for prostate cancer in the Medicare population. Journal Of Clinical Oncology 2012, 30: e15150-e15150. DOI: 10.1200/jco.2012.30.15_suppl.e15150.Peer-Reviewed Original ResearchHigh-risk groupShort life expectancyRisk groupsProstate cancerLife expectancyNational Comprehensive Cancer Network guidelinesAndrogen deprivation therapy useConcurrent androgen deprivation therapyEnd Results-Medicare databaseAndrogen deprivation therapyLow-risk cancersExternal beam radiationLow-risk groupLonger life expectancyDeprivation therapyNCCN guidelinesOlder patientsClinical factorsTherapy useGuideline recommendationsTumor characteristicsNetwork guidelinesCancer characteristicsRadiation therapyMedicare population